AF488-conjugated IL-17 Antibody (BL168)
(Synonyms: IL-17,IL-17-AF488,BL168)AF488-conjugated IL-17 Antibody (BL168) is a Mouse-derived and AF488 conjugated monoclonal antibody, targeting to IL-17.
-
Host:
Mouse
-
Isotype:
Mouse IgG1,κ
-
Application:
FC
-
Reactivity :
Human
-
Formulation:
Supplied in PBS (pH 7.2) containing 0.1% Proclin300 and protein stabilizer.
-
Conjugation:
AF488
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
Applications
| Application |
FC
FC: Flow Cytometry
|
|---|---|
| Dilution Ratio | 5 ul per 106 cells in a 100 µl suspension |
Product Details
Product Properties
-
Appearance
Solution
-
Formulation
Supplied in PBS (pH 7.2) containing 0.1% Proclin300 and protein stabilizer.
-
Storage & Stability
Stored at 2-8°C for 1 year, protect from light, do not freeze.
-
Shipping
Shipping with blue ice.
Background
-
Function
Interleukin-17 (IL-17) is a pro-inflammatory cytokine primarily produced by Th17 cells and other immune subsets, functioning as a key mediator in host defense and tissue inflammation[1][2][3]. IL-17 signals through the IL-17 receptor (IL-17R) complex, activating downstream NF-κB, MAPK, and JNK pathways, thereby promoting transcription of inflammatory mediators[1][4][5]. Mechanistically, IL-17 isoforms exhibit distinct expression patterns, with IL-17F predominating in enthesis tissue and peripheral CD4+ T cells, whereas IL-17A is less abundant[6]. In disease models, IL-17 contributes to psoriasis, psoriatic arthritis, necrotizing enterocolitis, and ischemic brain injury by amplifying local inflammation and modulating neutrophil and microglial responses[2][7][8][9][10][11]. Compared with related cytokines such as IL-17A and IL-17F, IL-17RA serves as a shared receptor subunit critical for signaling of multiple IL-17 isoforms except IL-17D, highlighting functional specificity among isoforms[4]. Pharmacologically, IL-17 inhibitors including secukinumab, ixekizumab, and brodalumab demonstrate potent anti-inflammatory effects in moderate-to-severe psoriasis and psoriatic arthritis, whereas A2a receptor agonists and PPARγ agonists modulate IL-17 production for experimental applications[12][13].
-
Isoforms & Post-Translational Modification
.
-
Synonyms
IL-17,IL-17-AF488,BL168
Documentation
References
[1]. Jiang R, et al. Effectiveness of exercise on perinatal depression and anxiety symptoms: A network meta-analysis and dose-response analysis. Int J Gynaecol Obstet. 2026 Jun;173(3):1308-1324. [Content Brief]
[2]. Lanna C, et al. Why targeted therapeutics have provided benefit in psoriasis: looking at IL-17 biology. Expert Rev Clin Pharmacol. 2022 Oct;15(10):1209-1224. [Content Brief]
[3]. Balato A, et al. Biologics that inhibit the Th17 pathway and related cytokines to treat inflammatory disorders. Expert Opin Biol Ther. 2017 Nov;17(11):1363-1374. [Content Brief]
[4]. Garg AV, et al. IL-17 signaling and A20: a balancing act. Cell Cycle. 2013 Nov 15;12(22):3459-60. [Content Brief]
[5]. Bosmann M, et al. Therapeutic potential of targeting IL-17 and IL-23 in sepsis. Clin Transl Med. 2012 Apr 27;1(1):4. [Content Brief]
[6]. Vidal S, et al. From Messengers to Receptors in Psoriasis: The Role of IL-17RA in Disease and Treatment. Int J Mol Sci. 2021 Jun 23;22(13):6740. [Content Brief]
[7]. Guo S, et al. Introducing CCD1 into isolated Rhodotorula strain enhances flavor production and improves cigar fermentation. Front Bioeng Biotechnol. 2024 Dec 3;12:1510075. [Content Brief]
[8]. Tremblay É, et al. IL-17-related signature genes linked to human necrotizing enterocolitis. BMC Res Notes. 2021 Mar 4;14(1):82. [Content Brief]
[9]. Maekawa T, et al. Antagonistic effects of IL-17 and D-resolvins on endothelial Del-1 expression through a GSK-3β-C/EBPβ pathway. Nat Commun. 2015 Sep 16;6:8272. [Content Brief]
[10]. Zhang B, et al. IL-17A Enhances Microglial Response to OGD by Regulating p53 and PI3K/Akt Pathways with Involvement of ROS/HMGB1. Front Mol Neurosci. 2017 Aug 31;10:271. [Content Brief]
[12]. Fletcher JM, et al. IL-17 in inflammatory skin diseases psoriasis and hidradenitis suppurativa. Clin Exp Immunol. 2020 Aug;201(2):121-134. [Content Brief]
[13]. Park SJ, et al. Peroxisome proliferator-activated receptor gamma agonist down-regulates IL-17 expression in a murine model of allergic airway inflammation. J Immunol. 2009 Sep 1;183(5):3259-67. [Content Brief]
Powered by Bioz
